FLX475: A CCR4 antagonist that mounts an immune response against a broad range of "charged" and virally associated tumors
We have completed a placebo-controlled, double-blinded dose-escalating Phase 1 clinical trial of FLX475 in 104 healthy volunteers. FLX475 was well tolerated and demonstrated dose-dependent inhibition of CCR4 with no observed immune-related adverse events or significant clinical adverse events. We are currently enrolling the Phase 2 portion of a Phase 1/2 study of FLX475 as a monotherapy, and in combination with pembrolizumab, in patients with “charged” tumors.